Devyser Diagnostics AB (publ) (STO:DVYSR)

Revenue by Product

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Hereditary Diseases	130.14M
Hereditary Diseases Growth	18.26%
Oncology	49.89M
Oncology Growth	47.33%
Transplantation	36.87M
Transplantation Growth	45.20%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Italy	87.50M
Europe, Middle East and Africa	62.10M
Europe, Middle East and Africa Growth	-55.45%
Germany	31.30M
North and South America	17.90M
North and South America Growth	29.71%
Sweden	11.10M
Sweden Growth	11.00%
Asia	7.00M
Asia Growth	14.75%